Table 2 Comparison between treatment and placebo groups for active trachoma and infection at 3, 6, and 12 months following TT surgery by multivariate analysis controlling for age, sex, and bilateral lid surgery.
| Total* (%) | Treatment group (%) | Placebo group (%) | p Value† | |
|---|---|---|---|---|
| Active trachoma (TF/TI)‡ | ||||
| Baseline | 88/148 (59.5) | 41/72 (56.9) | 47/76 (61.8) | NS (0.813) |
| 3 month follow up | 14/128 (10.9) | 5/64 (7.8) | 9/64 (14.1) | NS (0.911) |
| 6 month follow up | 17/114 (14.9) | 6/56 (10.7) | 11/58 (20.0) | NS (0.238) |
| 12 month follow up | 17/116 (14.7) | 8/57 (14.0) | 9/59 (15.3) | NS (0.891) |
| C trachomatis infection§ | ||||
| Baseline | 13/144 (9.0) | 7/69 (10.1) | 6/75 (8.0) | NS (0.993) |
| 3 month follow up | 4/118 (3.4) | 2/60 (3.3) | 2/58 (3.5) | NS (0.888) |
| 6 month follow up | 3/126 (2.4) | 1/62 (1.6) | 2/64 (3.1) | NS (0.967) |
| 12 month follow up | 5/118 (4.2) | 2/60 (3.3) | 3/58 (5.2) | NS (0.325) |
TF, follicular trachoma inflammation; TI, intense trachoma inflammation; NS, not significant.
*Denominator is based on number of eyelids; survival analysis over the 12 month time period was performed using a Kaplan‐Meier analysis with log rank test; results were similar to regression analysis.
†Multiple logistic regression controlling for age, sex, and bilateral lid surgery; statistical significance (p⩽0.05).
‡Denominator differs from the number of eyelids at baseline because of loss of trachoma grading information and loss to follow up (table 3).
§Denominator differs from the number of eyelids at baseline because of loss of conjunctival samples and loss to follow up (table 3).